PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
 

Press Releases

 
Trevigen, Inc.

Press Release


Receive press releases from Trevigen, Inc.: By Email RSS Feeds:

Cultrex® Mouse Laminin I Now Qualified “PathClear®”


Trevigen adds mouse Laminin I to PathClear® designated products for research involving cancer cell characterization and behavior.

Gaithersburg, MD, August 22, 2008 --(PR.com)-- Cancer researchers are finding more uses for mouse laminin I derived from EHS Sarcoma. Cancer cell characterization and modulation of behavior in response to putative attractants or inhibitors underlie important aspects of cancer research. Cell adhesion, migration, growth and differentiation are all studied using mouse laminin I along with other specialized proteins available from Trevigen, Inc.

Proteins derived from the EHS sarcoma have been found to harbor murine viruses such as LDEV, which may not be detected by MAP testing. The presence of these viruses could affect experimental results and cause incorrect conclusions. The reason that viruses may be present but not detected is that traditional manufacturing approaches do not remove all pathogens. Viruses may be present in low enough concentrations to be beneath the threshold of detection for the standard MAP Assays.

To solve these problems Trevigen has developed a new (patent applied for) manufacturing process which preserves both the biochemical integrity and the biological performance of mouse laminin I while eliminating the problem of low concentration viruses. In addition to the standard sterility, mycoplasma, endotoxin and MAP tests, the mouse laminin I is tested by PCR and cleared of a battery of 31 mouse pathogens including LDEV. This eliminates concern that contaminating agents may interfere and cause erroneous test results. Mouse laminin I produced by the new process is rigorously tested for contaminating organisms and designated PathClear®.

Trevigen, Inc. is a rapidly growing biotechnology company focused on the development of products and technology for cancer research, emphasizing apoptosis, DNA damage and repair, and cancer cell function and behavior. Trevigen has been a long-standing provider of quality reagents and kits for researchers investigating programmed cell death and DNA damage and repair. A logical extension of the focus on cancer research has been the recent development of assays for cancer cell function and behavior including angiogenesis, cell invasion and tumor formation. Currently, the product portfolio contains over 500 products categorized into four processes – Apoptosis, DNA Damage and Repair, Angiogenesis, and Oxidative Stress.

PathClear® BME, Mouse laminin I antibody, and other specialty proteins are also available separately from Trevigen. Visit www.trevigen.com or contact them at 1800-873-8443 or info@trevigen.com for more information.

###
Contact Information
Trevigen, Inc.
Belinda De Leon
1-800-TREVIGEN
Contact
http://www.trevigen.com
8405 Helgerman Ct.
Gaithersburg, MD 20877

Click here to view the list of recent Press Releases from Trevigen, Inc.
Promote Your Business